NEUROMYELITIS OPTICA SPECTRUM DISORDER

This study tests a drug called satralizumab in children aged 2 to 11 with a rare disease that attacks the nerves in the eyes and spine (NMOSD). The goal is to see how the drug works in the body and if it can prevent relapses. Only 8 children will take part, and they will receive …

This study tests a medicine called ravulizumab in children and teens (ages 2 to 17) with a rare disease called NMOSD that causes inflammation in the brain and spinal cord. The goal is to see if the drug can reduce the number of attacks and slow down disability. Participants recei…

This study tests a drug called inebilizumab in children aged 2 to 17 with neuromyelitis optica spectrum disorder (NMOSD), a rare disease that causes inflammation in the eyes and spinal cord. The goal is to see how the drug works in the body, how safe it is, and whether it can hel…

This study tests whether ofatumumab can reduce the number of relapses in people with a rare autoimmune disease called NMOSD. Five adults who have had at least two relapses in the past two years will receive the drug and be followed for one year. The goal is to see if the treatmen…

This study is a national registry that follows 1,500 women with multiple sclerosis (MS) or related conditions during pregnancy and after childbirth, along with their children. Researchers aim to learn how the disease and medications impact pregnancy, breastfeeding, and long-term …

This study is a long-term registry that follows about 122 adults with AQP4+ neuromyelitis optica spectrum disorder (NMOSD) who are already prescribed Alexion C5 inhibitor therapies. Researchers will collect data on relapse rates, safety, quality of life, and patient-reported outc…

This study follows 60 women with NMOSD who received UPLIZNA during pregnancy or within 6 months before getting pregnant. Researchers will collect information on pregnancy outcomes, such as birth defects, preterm birth, and low birth weight. The goal is to better understand the sa…